News >

Secondary Cytoreduction Does Not Improve Survival in Recurrent Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Thursday, Nov 14, 2019

Robert L. Coleman, MD, professor of gynecologic oncology and reproductive medicine, The University of Texas MD Anderson Cancer Center

Robert L. Coleman, MD

Secondary cytoreduction followed by chemotherapy was not found to improve overall survival (OS) compared with chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer, missing the primary endpoint of the phase III GOG-0213 trial.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication